IMMURON (IMRN) vs Longeveron Inc. (LGVN)
IMMURON and Longeveron Inc. are both Biotechnology companies. IMMURON and Longeveron Inc. are of similar size ($9.6M and $9.1M). IMMURON grew revenue faster over the last twelve months: −6.62% against −42.7%. IMMURON has the higher net margin (−262.7% vs −1,977.6%) and the higher return on invested capital (0.00% vs −4,549.0%). Across the 15 metrics below, IMMURON leads on 13 and Longeveron Inc. on 2.
Valuation
Profitability
| Metric | IMRN | LGVN | Biotechnology median |
|---|---|---|---|
| Gross margin | 71.28% | 69.76% | 65.16% |
| Operating margin | 0.00% | (1,992.84%) | 0.00% |
| Net margin | (262.71%) | (1,977.59%) | 0.00% |
| Free cash flow margin | 0.00% | (1,755.69%) | 0.00% |
| Return on equity | 0.00% | (203.61%) | (57.72%) |
| Return on assets | 0.00% | (145.64%) | (49.22%) |
| Return on invested capital | 0.00% | (4,549.04%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack